PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways
Authors:
Open Access
- 4 March 2014
- journal article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 34 (2) , e00094
Abstract
CDDP [cisplatin or cis-diamminedichloroplatinum(II)] and CDDP-based combination chemotherapy have been confirmed effective against gastric cancer. However, CDDP efficiency is limited because of development of drug resistance. In this study, we found that PAK4 (p21-activated kinase 4) expression and activity were elevated in gastric cancer cells with acquired CDDP resistance (AGS/CDDP and MKN-45/CDDP) compared with their parental cells. Inhibition of PAK4 or knockdown of PAK4 expression by specific siRNA (small interfering RNA)-sensitized CDDP-resistant cells to CDDP and overcome CDDP resistance. Combination treatment of LY294002 [the inhibitor of PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B or PKB) pathway] or PD98509 {the inhibitor of MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] pathway} with PF-3758309 (the PAK4 inhibitor) resulted in increased CDDP efficacy compared with LY294002 or PD98509 alone. However, after the concomitant treatment of LY294002 and PD98509, PF-3758309 administration exerted no additional enhancement of CDDP cytotoxicity in CDDP-resistant cells. Inhibition of PAK4 by PF-3758309 could significantly suppress MEK/ERK and PI3K/Akt signalling in CDDP-resistant cells. Furthermore, inhibition of PI3K/Akt pathway while not MEK/ERK pathway could inhibit PAK4 activity in these cells. The in vivo results were similar with those of in vitro. In conclusion, these results indicate that PAK4 confers CDDP resistance via the activation of MEK/ERK and PI3K/Akt pathways. PAK4 and PI3K/Akt pathways can reciprocally activate each other. Therefore, PAK4 may be a potential target for overcoming CDDP resistance in gastric cancer.Keywords
This publication has 32 references indexed in Scilit:
- PAK signaling in cancerCellular Logistics, 2012
- PAK as a therapeutic target in gastric cancerExpert Opinion on Therapeutic Targets, 2010
- Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancerCancer Chemotherapy and Pharmacology, 2006
- Pak1 Phosphorylation of Snail, a Master Regulator of Epithelial-to-Mesenchyme Transition, Modulates Snail's Subcellular Localization and FunctionsCancer Research, 2005
- Irinotecan plus Cisplatin Combination Against Metastatic Gastric Cancer: Phase II StudyMedical Oncology, 2005
- PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S TransitionCell Cycle, 2004
- Biology of the p21-Activated KinasesAnnual Review of Biochemistry, 2003
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- A Role for P21-Activated Kinase in Endothelial Cell MigrationJournal of Cell Biology, 1999
- A phase II study of cisplatin in advanced gastric cancerEuropean Journal of Cancer and Clinical Oncology, 1983